Physician profile
Vasutakarn E Chongthammakun
NPI 1932464732
$1,317.69
in general payments reported to CMS, 2019-2025
12 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Adult Congenital Heart Disease provider received nationally (typical 2025 total: $272).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $50.21 · 2022: $150 · 2023: $157 · 2024: $439 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.06 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $292.11 | 2024-2025 | Cobalt Dr Mri Surescan, Corevalve Evolut R |
| Bayer Healthcare Pharmaceuticals INC. | $266.89 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $157.08 | 2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2019 | |
| Boston Scientific Corporation | $121.17 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $93.89 | 2025 | Camzyos |
| Biosense Webster, INC. | $80.48 | 2024-2025 | Nuvision Ice Catheter, Na, Soundstar |
| Biotronik INC. | $50.21 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.44 | 2024-2025 | Lifevest |
| Novo Nordisk INC | $31.39 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $29.04 | 2022 | |
| Cvrx, INC. | $22.00 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasutakarn Chongthammakun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.